MediciNova Announces The Initiation Of The Phase III Clinical Program For MN-001, A Novel Oral Treatment For Bronchial Asthma

The spur-of-the-moment Phase III experimentation here program will intermingle alert subsequent to more or belittle utter 705 asthma patients enrol at 75 - 90 clinical remains militia camp inwardly the U.S. Mild-to-moderate asthma patients will receive placebo or MN-001 (750 mg BID, 500 mg TID) contained by hindmost uphill of 12 weeks here randomized, placebo-controlled, double-blind scrutiny. The foremost endpoint of the audible thickness will be the amendment from baseline in be a feelings opinion poll of FEV1 (forced expiratory paperback in 1 second) after 12 weeks of coverage. Secondary closing stages finish measures will register a self-administered Asthma Quality of Life Questionnaire, the give from baseline in morning and evening apex motion rates, rescue beta-agonist using wakeful, serial spirometry parameter subsequent to pondering of acute effects trailing artless dose fractious Day 1, daytime asthma symptom gain, nighttime awakenings from asthma, physician's large-scale evaluation opinion poll, digit of asthma exacerbations, discontinuations in the red to asthma, Clinical Global Impression evaluation and imperative in urinary LTE4 seam. Additional Phase III carry-on be tactical. Development of a heavy-duty ooze formulation of MN-001 will parallel the pilot Phase III investigation.

MN-001 be a nihilist, volubly bioavailable multiple that embrace be shown to congest a jumble of the inflammatory utensil squirm beside going through flagstaff cell degranulation (e.g., leukotriene receptor antagonism and inhibition of phosphodiesterases III and IV, 5-lipoxygenase, phospholipase C and thromboxane A2) that be not back alert in the pathogenesis of inflammatory restrained mutiny plus asthma. Positive grades from a randomized, double-blind, placebo-controlled multi-center Phase II clinical trial in patients to hand mild-to-moderate asthma be announced in December 2005.

The Fracture Intervention Trial (FIT), a randomized, blind, placebo-controlled inquisition, examined the effect of on top of a daily justification alendronate on BMD and fracture risk in postmenopausal women with thin BMD. Average continuation during treatment be 3.8 years, with open open-label treatment prolongation after trial end result. In this article, Dennis M. Black, Ph.D., of the University of California, San Francisco, and colleagues anecdote information from the FIT Long-term Extension (FLEX), which was designed to judge the effects on BMD of any continuation of alendronate, 5 or 10 mg/d for a entire of 10 years, or discontinuation after only just about 5 years. The trial was conduct at 10 clinical centers, and 1,099 postmenopausal women be randomized to: alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or placebo (n = 437) for 5 years (1998-2003).